• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    AbbVie (ABBV) Stock May Be 41% Undervalued On FDA Approval

    Simply Wall St·10/01/2026 18:21:25
    語音播報

    AbbVie’s AbbVie stock has had a strong multiyear run, and with the price recently closing at US$261.59, the key issue is whether that level is backed by the cash the business is expected to generate. Recent drug approvals, partnerships and data readouts all feed into those future cash flows, which is where the valuation debate now sits.

    • Over the past 5 years AbbVie has delivered a total return of 187.5%, which puts real weight on the question of whether the current share price is fully supported by its underlying cash streams.
    • The recent U.S. FDA approval of JUVMO for Parkinson’s disease, together with pipeline and AI driven R&D partnerships, can influence how investors think about the timing, durability and risk profile of AbbVie’s future cash flows.
    • Prefer to judge AbbVie on earnings? See why AbbVie's 73.7x P/E tells a different valuation story.

    The issue now is whether AbbVie’s current valuation can be explained by its cash flows when viewed through a Discounted Cash Flow (DCF) lens.

    If you want useful context around AbbVie and its cash flow story, compare it with companies filtered through 31 high quality undervalued stocks.

    Is AbbVie a Bargain on Cash Flow?

    The Discounted Cash Flow (DCF) approach here values AbbVie based on the cash it is forecast to return to shareholders. Over the last twelve months the group produced roughly $18.35b of free cash flow. The model then assumes this cash generation grows rather than shrinks over time, with projected free cash flows in the coming decade remaining in the tens of billions of dollars each year.

    Those cash projections, when discounted back, point to an estimated intrinsic value that the DCF suggests is substantially above the current share price of $261.59. The recent U.S. FDA approval of JUVMO for Parkinson’s disease is cited as support for the view that AbbVie’s late stage pipeline may help sustain those future cash flows, even though the exact contribution is still uncertain. Find out what AbbVie could be worth using our Discounted Cash Flow (DCF) estimate.

    The AbbVie Narrative: What Would Justify Today's Price?

    Simply Wall St Narratives pick up where the AbbVie DCF puzzle leaves off by explaining which paths for growth, margins and earnings would need to hold for the shares to be worth materially more or less than today’s price. Each narrative links a specific fair value to a clear storyline about AbbVie’s potential catalysts and key risks, so you can track over time which version of events appears to be unfolding on the Community page.

    One of the top community narratives on AbbVie: 6% undervalued

    "The key requirement for AbbVie is successfully executing on its pipeline and business development so that new immunology, oncology and neuroscience drugs replace revenue from declining products…"

    Discover why this Narrative puts AbbVie at 6% undervalued.

    AbbVie’s price is only one piece of the decision

    Before building an investment case around AbbVie, it helps to know that our broader checks have highlighted issues that could matter just as much as any cash flow model. Take a closer look at 4 warning signs before settling on a valuation.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.